title: Aptamer-drug conjugation for targeted tumor cell therapy.
abstract: Aptamers developed for applications in cancer therapy can improve the efficacy of drug treatment and enhance molecular imaging. Aptamers for these purposes are generated from SELEX (Systematic Evolution of Ligands by EXponential enrichment), more precisely cell-based SELEX, a process described in detail in this chapter. Experimental applications are also provided for aptamer-based drugs.
authors: Department of Chemistry, Shands Cancer Center, Moffitt Cancer Center, Center for Research at Bio/Nano Interface, UF Genetics Institute and McKnight Brain Institute, University of Florida, Gainesville, FL, USA. mjdonovan@ufl.edu
authors: Michael J
authors: MJ
authors: Donovan
authors: Ling
authors: L
authors: Meng
authors: Tao
authors: T
authors: Chen
authors: Yunfei
authors: Y
authors: Zhang
authors: Kwame
authors: K
authors: Sefah
authors: Weihong
authors: W
authors: Tan
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D052157:Aptamers, Nucleotide / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D001710:Biotin / Q000378:metabolism; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D008024:Ligands; D058990:Molecular Targeted Therapy / Q000379:methods*; D052156:SELEX Aptamer Technique / Q000379:methods*; D019809:Streptavidin / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D052157:Aptamers, Nucleotide; D008024:Ligands; D001710:Biotin; D004317:Doxorubicin; D019809:Streptavidin